Revotar Gets Positive Phase II Results in COPD

Revotar Biopharmaceuticals achieved positive results in Phase IIa Ozone Study with Bimosiamose for COPD. The study evaluated the effect of Bimosiamose on ozone-induced airway inflammation in healthy subjects with a new controlled breathing nebulizer device. The data supports further development of the new pan selectin antagonist in COPD.

The trial was designed as a double-blind, placebo controlled, randomized cross-over study comprising 18 non-smoking healthy ozone-responsive volunteers. Each subject received nebulized Bimosiamose solution or vehicle for four days twice daily in two subsequent periods separated by a wash-out phase (cross-over). Treatment was followed by ozone challenge and subsequent collection of induced sputum that was analyzed for cellular composition and non-cellular mediators.

Inhalation of Bimosiamose with a new controlled breathing nebulizer device was safe and well tolerated. Compared to placebo, the compound demonstrated a broad and significant anti-inflammatory effect on cellular and non-cellular sputum parameters.